Bradley T. Keller

Accuronix Therapeutics, Inc. develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk. The firm also develops new class of drugs that work by selectively targeting the s-2 (sigma-2) receptor on cancer cells to deliver cytotoxic payloads. Its s-2 receptors are expressed on the surface of rapidly proliferating cancer cells. The company was founded by William Hawkins and Robert Mach and is headquartered in St. Louis, MO.

Skandalaris Center (Skandalaris Center) is a venture capital firm subsidiary of Olin Business School founded in 2001 by Bob Skandalaris. The firm is headquartered in St. Louis, Missouri.

Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA.